不同剂量辛伐他汀治疗慢性阻塞性肺疾病急性加重的效果

doi:10.3969/j.issn.2095-9400.2019.11.011

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (1215 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the efficacy and safety of different doses of simvastatin in the treatment of patients with chronic obstructive pulmonary disease (COPD) at acute exacerbation stage. Methods: Totally 180 patients with acute exacerbation of COPD were randomly divided as the conventional simvastatin (40 mg/d)
treatment group (group A), the low-dose simvastatin (20 mg/d) treatment group (group B), and the conventional treatment control group (group C). The primary indicator was C-reactive protein (CRP) and the secondary indicators included interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), arterial blood gas, lung function, a 6-minute walk test (6MWD). Results: 180 patients entered the randomized group and three of them fell off. Compared with the situation before treatment, the above inflammation indicators, including CRP, IL-6 and TNF-α decreased significantly after treatment (P<0.01), and they were significantly lower in group A and group B (P<0.05) than group C, with group A the lowest (P<0.05). The arterial blood gas, lung function and 6MWD index of each group were improved (P<0.01), and no significant difference was found between the three groups after treatment (P>0.05). Conclusion: Simvastatin, especially the conventional doses of simvastatin, can inhibit patients with COPD from systemic inflammatory response at acute exacerbation stage.

Key words： simvastatin acute exacerbation, chronic obstructive pulmonary disease C-reactive protein interleukin-6 tumor necrosis factor-alpha

Received: 17 April 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHI Qiong
	ZNENG Jiyang
	DAI Xinjian
	ZHANG Baoyi
	ZHANG Zhiyuan

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.11.011 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I11/842

[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[2] Global Initiative for Chronic Obstructive Lung Disease.Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2019 report [EB/OL].(2019-04-17)[2018-12-02]. https://goldcopd.org/gold-reports/.
[3] YOUNG R P, HOPKINS R, EATON T E. Pharmacological actions of statins: potentialutility in COPD[J]. Eur Respir Rev, 2009, 18(114): 222-232.
[4] LAWES C M, THORNLEY S, YOUNG R, et a1. Statin usein COPD patients is associated with a reduction in mortality: a national cohortstudy[J]. Prim Care Respir, 2012, 21(1): 35-40.
[5] 郑方算, 田飒, 黄剑臻. 瑞舒伐他汀联合舒血宁注射液治疗慢性阻塞性肺疾病急性加重期病人52例的疗效[J]. 药学服务与研究, 2015, 15(6): 478-480.
[6] 于虹, 黄天霞, 韦球, 等. 瑞舒伐他汀辅助正压通气对AE-COPD患者肺部通气功能、SGRQ评分及C反应蛋白的影响[J]. 实用药物与临床, 2017, 20(3): 265-267.
[7] 周曦, 严峻海, 张柏膺. 他汀类药物对慢性阻塞性肺疾病稳定期患者炎性因子影响作用研究[J]. 临床肺科杂志, 2015, 20(3): 450-452.
[8] 田昌荣, 聂毛晓, 申潇竹. 瑞舒伐他汀钙对慢性阻塞性肺病急性发作期患者炎症因子的影响[J]. 中国老年学杂志, 2013, 33(17): 4297-4298.
[9] SANJA M, JOZSEF P, SANJA P G, et al. Cytokinesandstatintherapy in chronic obstructive pulmonary disease pa-tients[J]. Scand J Clin Lab Invest, 2018, 78(7-8): 533-538.
[10] 刘瑞琪, 王雪, 周萍, 等. 他汀类药物治疗AECOPD的临床研究[J]. 实用药物与临床, 2015, 18(6): 745-747.
[11] PATYK I, RYBACKI C, KALICKA A, et al. Simvastatin therapy and bronchoalveolar lavage fluid biomarkers in chronic obstructive pulmonary disease[J]. Adv Exp Med Biol,
2019, 1150: 43-52.
[12] ZHANG M Z, QIAN D H, XU J C. et al. Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases[J]. J Thorac Dis, 2017, 9(8): 2437-2446.
[13] 庞东, 黄进, 李曾凡. 阿托伐他汀和辛伐他汀治疗慢性阻塞性肺疾病的对比研究[J]. 中国当代医药, 2015, 7(22): 132-134.
[14] FRANCHI M, VETRANO D L, ROBERTO G, et al. Adherence of elderly patients with cardiovascular disease to statins and the risk of exacerbation of chronic obstructive pulmonary disease: Evidence from an Italian Real-World Investi-gation[J]. Drugs Aging, 2018, 35(12): 1099-1108.
[15] YILDIZELI Ş O, BALCAN B, ERYÜKSEL E, et al. Influence of statin therapy on exacerbation frequency in patients with chronic obstructive pulmonary disease[J]. Turk Thorac J, 2017, 18(2): 29-32.
[16] 叶环, 施肖红, 吴厉锋, 等. 瑞舒伐他汀钙对老年重度重叠综合征患者预后的影响[J]. 温州医科大学学报, 2015, 45(11): 807-810.